Management of Schizophrenia with Substance Use Disorders

Psychiatric Clinics of North America

Volumn 32, Issue 4, 2009, Pages 821-833

  Lybrand, Janice ^a   Caroff, Stanley ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alcohol; Cannabis; Cocaine; Nicotine; Schizophrenia; Substance use disorders

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DESIPRAMINE; DISULFIRAM; FLUPHENAZINE; HALOPERIDOL; NALTREXONE; NEUROLEPTIC AGENT; NICOTINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ALCOHOL ABUSE; ALCOHOLISM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CHOICE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; EMOTIONALITY; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; PATIENT ATTITUDE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SMOKING CESSATION; SUBSTANCE ABUSE; TOBACCO DEPENDENCE;

ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DUAL (PSYCHIATRY); DISULFIRAM; HUMANS; PSYCHOTHERAPY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS;

EID: 70450225560     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2009.09.002     Document Type: Review

References (75)

1. Regier D.A., Farmer M.E., Rae D.S., et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264 (1990) 2511-2518
2. Cantor-Graee E., Nordstrom L.G., and McNeil T.F. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 48 (2001) 69-82
3. Chamber R.A., Krystal J.H., and Self D.W. A neurobiological basis for substance abuse co-morbidity in schizophrenia. Biol Psychiatry 50 (2001) 71-83
4. Mueser K.T., Essock S.M., Drake R.E., et al. Rural and urban differences in patients with a dual diagnosis. Schizophr Res 48 (2001) 93-107
5. Thorne S.L., Malarcher A., Maurice E., et al. Cigarette smoking among adults-United States 2007. Morb Mortal Wkly Rep 57 (2008) 1221
6. Lasser K., Boyd J.W., Woolhandler S., et al. Smoking and mental illness: a population-based prevalence study. JAMA 284 20 (2000) 2606-2610
7. deLeon J., and Diaz F.J. A meta-analysis of world-wide studies demonstrating an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 76 (2005) 135-157
8. Kelly C., and McCreadie R.M. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 156 11 (1999) 1751-1757
9. Gregg L., Barrowclough C., and Haddock G. Reasons for increased substance abuse in psychosis. Clin Psychol Rev 27 (2007) 494-510
10. Mauri M., Volonteri L., DeGaspari I., et al. Substance abuse in first-episode schizophrenic patients; a retrospective study. Clin Pract Epidemiol Ment Health 23 (2006) 2-4
11. Salyers M.P., and Mueser K.T. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res 48 (2001) 109-123
12. Caton C.L., Shrout P.E., Eagle P.F., et al. Risk factors for homelessness among schizophrenic men: a case-control study. Am J Public Health 84 (1994) 265-270
13. Khantzian E.J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 142 (1985) 1259-1264
14. Khantzian E.J. The self-medication hypothesis of substance use disorder: a reconsideration and recent applications. Harv Rev Psychiatry 4 (1997) 231-244
15. Mueser K.T., Bellack A.S., and Blanchard J.J. Comorbidity of schizophrenia and substance abuse: implications for treatment. J Consult Clin Psychol 60 (1992) 845-856
16. Dixon L., Haas G., Weiden P.J., et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 148 (1991) 224-230
17. Duke P.J., Pantelis C., and Barnes T.R.E. South Westminster schizophrenia survey: alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 164 (1994) 630-636
18. Dalack G.W., Healy D.J., and Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 155 (1998) 1490-1501
19. Kumari V., Soni W., and Sharma T. Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia. Hum Psychopharmacol 16 (2001) 321-326
20. George T.P., Vessicchio J.C., Termine A., et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26 (2002) 75-85
21. Grant B.F. Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States: results of the national longitudinal alcohol epidemiologic survey. J Stud Alcohol 58 (1997) 464-473
22. Mueser K.T., Drake R.E., and Wallach M.A. Dual diagnosis: a review of etiological theories. Addict Behav 23 (1998) 717-734
23. Hambrecht M., and Hafner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 40 (1996) 1155-1163
24. Andreasson S., Allebeck P., Engstrom A., et al. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet 2 8574 (1987) 1483-1486
25. Hambrecht M., and Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiologic perspective. Aust N Z J Psychiatry 34 (2000) 468-475
26. Kendlar K.S., and Gardner C.O. The risk for psychiatric disorders in relative of schizophrenia and control probands: a comparison of three independent studies. Psychol Med 27 (1997) 411-419
27. Kendlar K.S. A twin study of individuals with both schizophrenia and alcoholism. Br J Psychiatry 147 (1985) 48-53
28. Blanchard J.B., Brown S.A., Horan W.P., et al. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin Psychol Rev 20 2 (2000) 207-234
29. Cooper M.L., Russell M., Skinner J.B., et al. Stress and alcohol use: moderating effects of gender, coping, and alcohol expectancies. J Abnorm Psychol 101 (1992) 139-152
30. Choulijan T.L., Shumway M., Balanzio E., et al. Substance use among schizophrenia outpatients: prevalence, course and relation to financial status. Ann Clin Psychiatry 7 (1995) 19-24
31. Tracy H., Josiassen R.C., and Bellak A.S. Neuropsychology of dual diagnosis: understanding the combined effects of schizophrenia and substance use disorders. Clin Psychol Rev 15 (1995) 67-97
32. Owens R.R., Fisher E.P., Booth B.M., et al. Medication non-compliance and substance abuse among patients with schizophrenia. Psychiatr Serv 47 (1998) 853-858
33. Mason P., Harrison G., Glazebrook C., et al. The course of schizophrenia over 13 years: a report from the International Study on Schizophrenia (ISoS) coordinated by the World Health Organization. Br J Psychiatry 169 (1996) 580-586
34. Swofford C.D., Kasackow J.W., Schellen-Gilkey C., et al. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res 20 (1996) 145-151
35. Gupta S., Hendricks S., Kendel A., et al. Relapse in schizophrenia: is there a relationship to substance abuse?. Schizophr Res 20 (1998) 153-156
36. Bartels S.J., Teague G.B., Drake R.E., et al. Service utilization and costs associated with substance abuse among rural schizophrenic patients. J Nerv Ment Dis 181 (1993) 227-232
37. Dickey B., Azeni H., Drake R.E., et al. Persons with dual diagnosis of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health 86 (1996) 973-977
38. Cuffel B.J. Prevalence of estimates of substance abuse in schizophrenia and their correlates. J Nerv Ment Dis 180 (1992) 589-592
39. Cuffel B.J., Sumway M., and Choulijan T. A longitudinal study of substance use and community violence in schizophrenia. J Nerv Ment Dis 182 (1994) 704-708
40. Seibyl J.P., Satel S.L., Anthony D., et al. Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis 181 1 (1993) 31-37
41. Goodman L.A., Slayers M.P., Mueser K.T., et al. Recent victimization in women and men with severe mental illness: prevalence and correlates. J Trauma Stress 14 (2001) 615-632
42. Cuffel B.J. Violent and destructive behavior among the severely mentally ill in rural areas; evidence from Arkansas' community mental health system. Community Ment Health J 30 (1994) 495-504
43. Abram K.M., and Teplin L.A. Co-occurring disorders among mentally ill jail detainees: implications for public policy. Am J Psychol 46 (1991) 1036-1045
44. Cividini A., Pistorio A., Regazetti A., et al. Hepatitis C virus infection among institutionalized psychiatric patients: a regression analysis of indicators of risk. J Hepatol 27 (1997) 455-463
45. Rosenberg S.D., Goodman L.A., Osher F.C., et al. Prevalence if HIV, hepatitis B and hepatitis C in people with severe mental illness. Am J Public Health 91 (2001) 31-37
46. Taubes T., Galanter A., Dermatis H., et al. Crack cocaine and schizophrenia as risk factors for PPD reactivity in the dually diagnosed. J Addict Dis 17 3 (1998) 63-74
47. Dickey B., Azeni H., Weiss R., et al. Schizophrenia, substance use disorders and medical co-morbidity. J Ment Health Policy Econ 3 (2000) 27-33
48. Brady K., Anton R., and Ballenger J.C. Cocaine abuse among schizophrenic patients. Am J Psychiatry 147 (1990) 1164-1167
49. Zaretsky A., Rector N.A., Seeman M.V., et al. Current cannabis use and tardive dyskinesia. Schizophr Res 11 (1993) 3-8
50. Harris E.C., and Barraclough B. Excess mortality of mental disorders. Br J Psychiatry 173 (1998) 11-53
51. Brown S., Inskip H., and Barraclough B. Causes of excess mortality of schizophrenia. Br J Psychiatry 177 (2000) 212-217
52. Himmelhoch S., Lehman A., Kreyenbuhl J., et al. Prevalence of chronic obstructive pulmonary disease among those with serious mental illness. Am J Psychiatry 161 12 (2004) 2317-2319
53. Drake R.E., and Mueser K.T. Substance abuse comorbidity. In: Lieberman J.A., and Murray R.M. (Eds). Comprehensive care of schizophrenia (2001), Martin Dunitz, London 243
54. Ziedonis D.M., Smelson D., Rosenthal R.N., et al. Improving the care of individuals with schizophrenia and substance use disorder: consensus recommendations. J Psychiatr Pract 11 5 (2005) 315-337
55. Maisto S.A., Carey M.P., Carey K.B., et al. Use of AUDIT and the DAST-10 to identify alcohol and drug use disorders among adults with severe and persistent mental illness. Psychol Assess 12 (2000) 186-192
56. Rosenberg S.D., Drake R.E., Wolford G.L., et al. The Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness. Am J Psychiatry 155 (1998) 232-238
57. Drake R.E., Essock S.M., Shaner A., et al. Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv 52 (2001) 469-476
58. Drake R.E., O'Neal E.L., and Wallach M.A. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental illness and substance use disorders. J Subst Abuse Treat 34 1 (2008) 123-138
59. Bellack A.S., Bennett M.E., Gearon J.S., et al. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 63 (2006) 426-432
60. Haddock G., Barrowclough C., Tarrier N., et al. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes for a randomized controlled trial. Br J Psychiatry 183 (2003) 418-426
61. Brunette M.F., Mueser K.T., and Drake R.E. A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev 23 (2004) 471-481
62. McEvoy J.P., Freundenreich O., Levin E.D., et al. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 119 (1995) 124-126
63. George T.P., Ziedonis D.M., Feingold A., et al. Nicotine transdermal patch and atypical antipsychotic medication for smoking cessation in schizophrenia. Am J Psychiatry 157 (2000) 1835-1842
64. McEvoy J.P., Freudenreich O., and Wilson W.H. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 46 (1999) 125-129
65. Zimmet S.V., Strous R.D., Burgess E.S., et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychiatry 20 (2000) 94-98
66. Drake R.E., Xie H., McHugo G.I., et al. The effects of clozapine on alcohol and drug use disorder among patients with schizophrenia. Schizophr Bull 26 (2000) 441-449
67. Smelson D.A., Losonczy M.F., Davis C.W., et al. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 47 (2002) 671-675
68. Green A.I., Burgess E.S., Dawson R., et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 60 (2003) 81-85
69. Green A.I., Zimmet S.V., Strous R.D., et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harv Rev Psychiatry 6 (1999) 287-296
70. Sayers S., Campbell E.C., Kondrich J., et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 193 (2005) 379-386
71. Smelson D.A., Ziedonis D., Williams J., et al. The efficacy of olanzapine for decreasing cue-elicited cravings in individuals with schizophrenia and cocaine dependence. J Clin Psychopharmacol 26 (2006) 9-12
72. Petrakis I.L., O'Malley S., Rounsaville B., et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 172 3 (2004) 291-297
73. Meuser K.T., Noordsy D.L., and Wolfe R. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 12 3 (2003) 242-252
74. Ziedonis D., Richardson T., Lee E., et al. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 28 3 (1992) 309-314
75. Evins A.E., Cather C., Culhane M.A., et al. A 12-week double-blind placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 27 4 (2007) 380-386